Official Title: “Longitudinal Study of Efficacy of Standard Albendazole Treatment Versus Levamisole/Pyrantel Pamoate on Soil Transmitted Helminth Infections”

Field epidemiological studies undertaken during 2005 in four village locations in Northern Unguja, Zanzibar examined mothers and their pre-school aged children for helminth infections.

The prevalence of Ascaris lumbricoides was found to have remained relatively high despite community-wide treatment with the mass administration of Albendazole (a WHO recommended de-wormer) in coordination with community vitamin A supplementation.

One hypothesis for this is that the children and mothers had Ascaris infections more tolerant to Albendazole that subsequently failed to clear. It is necessary to compare the present drug efficiency of Albendazole (first-line de-wormer) with Levamisole (second-line de-wormer) on STH infections such patients a case-control setting to shed light on the putative resistance of local Ascaris/Trichuris to albendazole.

In so doing, this should clarify whether there is resistance developing towards Albendazole and have possible implications for introducing combination therapies of Levamisole and Albendazole for first line de-worming mothers and their children in the future.

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Subject), Parallel Assignment, Efficacy Study

Study Primary Completion Date: September 2006

The study was conducted in 10 villages on Unguja Island representative of urban, semi-urban and rural environments. After liaison with the local Shehia (the elected community leader) mothers and their children aged between 6 months and 5 years old were invited to attend a walk-in mobile clinic. In accordance with WHO sample size recommendations of 30 individuals per site and to cater for drop-out/non-compliance, target enrolment was about 50 mother and child pairs at each study village.

Stool specimens were transported to the Helmtin Control Laboratory Unguja laboratory for visual inspection of stool consistency and presence of blood, after which a single Kato-Katz thick smear (41.7mg) was prepared. Eggs of all STH species were counted by inspection at 100x microscopy and expressed as a tally of eggs per gram (EPG). To ensure consistency of egg counts, slides were read by the same two technicians for each study village.

10 Mother and child pairs found positive for Ascaris and/or Trichuris were randomised, by coin tossing, to receive either a single tablet of ALB (400mg) or an appropriate dose of LEV (2.5 mg/kg). A parasitological follow-up took place 18 days after treatment where a requested stool sample was analyzed by a single Kato-Katz thick smear for assessment of STH clearance.

In accordance with WHO's 'no survey without service' all attendees were given an additional ALB tablet.

Intervention(s) in this Clinical Trial

• Drug: Albendazole
  • Single oral dose of 400mg
• Drug: Levamisole
  • Single oral dose of 2.5mg/kg

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: 1
  • 1 Individuals treated with Albendazole
• Active Comparator: 2
  • Individuals treated with Levamisole

Primary Measures

• Clearance of STH faecal eggs in patient stool
  • Time Frame: 18 days
    Safety Issue?: No

Inclusion Criteria:

• Presently with soil-transmitted helminthiasis

Exclusion Criteria:

• absence of soil-transmitted helminthiasis

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 1 Year

Maximum Age for this Clinical Trial: 45 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Natural History Museum, United Kingdom

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00659997

Study ID Number: NHMDEWORMING

ClinicalTrials.gov Identifier: NCT00659997

Health Authority: United Kingdom: Research Ethics Committee